Sun Liying, Ye Xuhui, Wang Linlin, Yu Junping, Wu Yan, Wang Minpeng, Dai Lihua
Intensive Care Unit, Shidong Hospital, Shanghai, China.
Front Neurosci. 2022 Jun 29;16:942188. doi: 10.3389/fnins.2022.942188. eCollection 2022.
Cerebral small vessel disease (CSVD) is often referred to as "collaterals disease" in traditional Chinese medicine (TCM), and commonly includes ischemic and hemorrhagic CSVD. TCM has a long history of treating CSVD and has demonstrated unique efficacy. Buyang Huanwu Decoction (BHD) is a classical TCM formula that has been used for the prevention and treatment of stroke for hundreds of years. BHD exerts its therapeutic effects on CSVD through a variety of mechanisms. In this review, the clinical and animal studies on BHD and CSVD were systematically introduced. In addition, the pharmacological mechanisms, active components, and clinical applications of BHD in the treatment of CSVD were reviewed. We believe that an in-depth understanding of BHD, its pharmacological mechanism, disease-drug interaction, and other aspects will help in laying the foundation for its development as a new therapeutic strategy for the treatment of CSVD.
脑小血管病（CSVD）在中医中常被称为“络病”，通常包括缺血性和出血性CSVD。中医治疗CSVD历史悠久，且已显示出独特疗效。补阳还五汤（BHD）是一个经典的中医方剂，数百年来一直用于预防和治疗中风。BHD通过多种机制对CSVD发挥治疗作用。在本综述中，系统介绍了关于BHD和CSVD的临床及动物研究。此外，还对BHD治疗CSVD的药理机制、活性成分及临床应用进行了综述。我们认为，深入了解BHD及其药理机制、疾病-药物相互作用等方面将有助于为其作为治疗CSVD的新治疗策略的开发奠定基础。
